May 22, 2020 Not intended for U.S. and UK Media Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancerRead more
May 19, 2020 Nine internationally recognized experts join Sustainability Council Independent external council to advise Bayer’s Board of Management on consistent implementation of its sustainability targetsRead more
May 13, 2020 Not intended for U.S. and UK Media - New ARAMIS Phase III data to be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program Nubeqa™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancerRead more